Tag - CBMG

Developments

Cellular Biomedicine receives going private proposal

The board of Cellular Biomedicine Group (NASDAQ:CBMG) received a preliminary non-binding proposal from a consortium led by Tony Liu, CEO of Cellular, to acquire all the shares outstanding at a price of $19.50 each in a...

November 11, 2019

Markets

TBIG starts Cellular Biomedicine at buy; PT $19

TBIG launched coverage of Cellular Biomedicine Group (NASDAQ:CBMG) with a “buy” rating and $19 price target. The stock closed at $14.84 on Sept. 16. Cellular has been developing its cGMP grade cell therapy manufacturing...

September 17, 2019

Tag - CBMG

Cellular Biomedicine receives going private proposal

TBIG starts Cellular Biomedicine at buy; PT $19

General

More